Clinical Trial Detail

NCT ID NCT02999477
Title A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

breast cancer

Therapies

Pembrolizumab

Nab-paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST